A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Sponsor
- Peking Union Medical College Hospital
- Study ID
- NCT03251443
- Phase
- PHASE2
- Status
- Completed
Conditions
- Intrahepatic Cholangiocarcinoma
- Second-line Treatment
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Apatinib — DRUG500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study Details
The purpose of this study is to explore the efficacy and safety of second-line treatment of apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety, progression free and overall survival. The primary endpoint of this study is objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).
Key Dates
- Start date
- Aug 8, 2017
- Status verified
- Jul 2019
- Primary completion
- Mar 8, 2019
- Completion
- May 8, 2019
Study Design
- Enrollment
- 34 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ApatinibA molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
Primary Outcome Measure
Progression-free Survival (PFS) [ Time Frame: six months ]
Related Studies
- Regional or Extend LymphAdenectomy During Resection of Intrahepatic CholangiocarcinomaRecruiting · Second Affiliated Hospital, School of Medicine, Zhejiang University · Baltimore, Maryland
- Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With SurgeryPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Bethesda, Maryland
- An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaPHASE2 · Recruiting · Virogin Biotech Canada Ltd · Phoenix, Arizona
- The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control CancerPHASE2 · Recruiting · Inova Health Care Services · Fairfax, Virginia